On March 25, AstraZeneca announced that the European Medicines Agency (EMA) officially approved its SGLT-2 inhibitor, Forxiga (Dalagide) as adjunctive therapy for insulin, for optimal use of optimal doses of insulin to control poor blood sugar. Type 1 diabetes patients (BMI ≥ 27). This is the first time that… Continue Reading SGLT-2 inhibitors first approved for the treatment of type 1 diabetes
On March 4, Novartis published a clinical trial of a Phase III study of Cosentyx in the treatment of moderate to severe plaque psoriasis at the 2019 Annual Meeting of the American Academy of Dermatology (AAD2019). The reason for this study is that 441 of the 543 patients with… Continue Reading The third phase of clinical data of Cosynmyx China, a new psoriasis drug, was released for the first time: excellent efficacy and significant benefit
On February 27th, Bayer announced its 2018 financial report. The Group achieved a total revenue of 39.586 billion euros, an increase of 13.1% compared with 2017. The total revenue of the pharmaceutical business was 16.746 billion euros (-0.6%), the income from consumer health business was 5.45 billion euros (-7%),… Continue Reading Bayer 2018 earnings report: Acarbose reverse growth! New drug development is broken, the structure is about to be adjusted
In November last year, the Financial Times discussed some of the characteristics of the transformation of the Chinese pharmaceutical industry at the “2018 Pharmaceutical & Biotechnology Summit” held in London. At the meeting, the host threw out a poll of “When do you think China might become an important… Continue Reading The new road of Chinese pharmaceutical companies
On February 19, Intercept announced that olbecholic acid (OCA) has achieved positive results in the mid-phase analysis of the key phase III REGENERATE study of patients with nonalcoholic steatohepatitis (NASH) with grade 2 to 3 liver fibrosis. Efficacy data from the primary endpoint showed: 1) At the 18th month… Continue Reading NASH’s new drug wins its first phase III clinical victory, and Abecholic acid is about to open a $40 billion market
On February 6, the FDA approved the introduction of Cablivi (caplacizumab-yhdp) injection developed by Sanofi’s subsidiary Ablynx for plasma exchange and immunosuppressive therapy for adult acquired thrombotic thrombocytopenic purpura (aTTP). On September 3, 2018, the European Union has approved the application for the listing of Cablivi for this indication.… Continue Reading FDA approves first Nanobody to treat acquired thrombotic thrombocytopenic purpura
On January 18th, Celgene announced a partnership with Kyn Therapeutics, a startup that is committed to developing immune systems against cancer. Kyn is an investment by Atlas Venture and OrbiMed and is headquartered in Boston. Celgene will pay Kyn a down payment of $80 million and an undisclosed equity… Continue Reading Celgene’s heavy trading
Recently, the international authoritative medical journal BMJ published a highly subversive heavyweight paper, which caused great sensation in the medical field. A large cohort study based on nearly a million people showed that the use of ACEI-type antihypertensive drugs increased the overall risk of lung cancer by 14% compared… Continue Reading A large follow-up study of 1 million people revealed that the classic antihypertensive drug ACEIs took more than 10 years, and the risk of lung cancer increased by 31%.
In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.
On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked